Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Abingdon Health PLC ( (GB:ABDX) ) has shared an update.
Abingdon Health reported a 45% rise in first-half FY26 revenues to £4.5m, underpinned by several major commercial contracts and grant-funded development work, while cash more than doubled to £3.6m following an October equity raise of £3.2m to fund its US expansion and support higher-value projects. The board reaffirmed full-year FY26 revenue guidance of £12.6m despite deferring revenue from key customer Find Out From Home into FY27, and said it expects a profitable, cash-generative second half as it scales lateral flow development and manufacturing capacity at its Madison, Wisconsin facility, reinforcing confidence in the company’s growth trajectory and commercial momentum.
The most recent analyst rating on (GB:ABDX) stock is a Hold with a £6.50 price target. To see the full list of analyst forecasts on Abingdon Health PLC stock, see the GB:ABDX Stock Forecast page.
Spark’s Take on GB:ABDX Stock
According to Spark, TipRanks’ AI Analyst, GB:ABDX is a Neutral.
Abingdon Health PLC’s overall stock score is primarily influenced by its mixed financial performance, with strong revenue growth overshadowed by profitability and cash flow challenges. The technical analysis indicates a neutral trend, lacking strong momentum. The valuation is unattractive due to a negative P/E ratio and no dividend yield. These factors collectively result in a moderate overall score.
To see Spark’s full report on GB:ABDX stock, click here.
More about Abingdon Health PLC
Abingdon Health plc is a UK-headquartered med-tech contract service provider specialising in the development, manufacturing and regulatory support of rapid diagnostic tests, particularly lateral flow assays, for an international customer base. Through its CDMO and CRO operations, along with regulatory consultancies Compliance Solutions (Life Sciences) and IVDeology and its Abingdon Analytical testing unit, the group supports clients across infectious disease, clinical and companion diagnostics, animal health and environmental testing, helping bring in vitro diagnostic and medical device products to market in the UK, EU, USA and other territories.
Average Trading Volume: 111,963
Technical Sentiment Signal: Sell
Current Market Cap: £15.69M
For detailed information about ABDX stock, go to TipRanks’ Stock Analysis page.